For instance, the presence of TP53 mutations has been shown to be associated with poor prognosis in azacitidine-treated MDS patients [7], and in LEN-treated MDS or AML patients with del[5q] [8,9]. The gene discussed is TP53; the disease is myelodysplastic syndrome.